Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00430781
Reclutando
Fase 3
ClinicalTrials.gov
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
INTERVENTIONAL
Inicio: 31 de mar de 2023
ID: NCT05774951
Completado
Fase 2
ClinicalTrials.gov
Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma
INTERVENTIONAL
Inicio: 1 de dic de 1997
ID: NCT00003445
Terminado
ClinicalTrials.gov
TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
INTERVENTIONAL
Inicio: 13 de feb de 2019
ID: NCT04436120
Aún no recluta
ClinicalTrials.gov
Development and Validation of an Obstetric Organ Dysfunction Score to Predict Mortality in Intensive Care Unit: A Multicenter, Prospective, Cohort Study
OBSERVATIONAL
Inicio: 1 de ago de 2025
ID: NCT07068022
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment
INTERVENTIONAL
Inicio: 1 de feb de 2011
ID: NCT01250379
Completado
Fase 2
ClinicalTrials.gov
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer
INTERVENTIONAL
Inicio: 1 de dic de 2006
ID: NCT00371345
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 2 de dic de 2015
ID: NCT02594371
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy
INTERVENTIONAL
Inicio: 7 de jun de 2023
ID: NCT05646862
Completado
Fase 3
ClinicalTrials.gov
A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.
INTERVENTIONAL
Inicio: 1 de may de 2009
ID: NCT01095003
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
INTERVENTIONAL
Inicio: 16 de abr de 2009
ID: NCT00849667
Reclutando
Fase 3
ClinicalTrials.gov
IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment
INTERVENTIONAL
Inicio: 11 de sept de 2025
ID: NCT06926868
Completado
Fase 3
ClinicalTrials.gov
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
INTERVENTIONAL
Inicio: 30 de nov de 2016
ID: NCT02941926
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
INTERVENTIONAL
Inicio: 22 de may de 2025
ID: NCT06952504
Completado
Fase 4
ClinicalTrials.gov
A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 20 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission: NICHD P1081
INTERVENTIONAL
Inicio: 5 de sept de 2013
ID: NCT01618305
Reclutando
Fase 3
ClinicalTrials.gov
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
INTERVENTIONAL
Inicio: 27 de sept de 2024
ID: NCT06492616
Completado
Fase 4
ClinicalTrials.gov
A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
INTERVENTIONAL
Inicio: 1 de sept de 2002
ID: NCT00365170
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 3 de ago de 2022
ID: NCT05306340
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy
INTERVENTIONAL
Inicio: 1 de ago de 2009
ID: NCT00883116
Completado
ClinicalTrials.gov
Comparative Effect of Percutaneous Microelectrolysis With or Without Current Emission in the Treatment of Cervical Pain in Myofascial Trigger Points of the Trapezius
INTERVENTIONAL
Inicio: 16 de ago de 2022
ID: NCT05524623
Anterior
1
...
8
9
10
...
434
Siguiente
Filtros